
Sign up to save your podcasts
Or


The FDA is expected to approve Tirzepatide for weight loss sometime this year and we think it could become the best selling drug of ALL TIME. Today on Dumb Money, we'll weigh the data, size-up the opportunity, and give you the skinny on our diet drug investment thesis.
Here are the GLP-1 RA drug makers and their drugs:
Eli Lilly (ticker LLY)
Tirzepatide sold as Mounjaro for diabetes. Weight loss version expected in 2023.
Dulaglutide sold as Trulicity.
Novo Nordisk (ticker NVO)
Semaglutide sold as Ozempic and Rybelsus for diabetes and Wegovy for weight loss.
Liraglutide sold as Victoza for diabetes and Saxenda for weight loss.
By Dumb Money4.7
110110 ratings
The FDA is expected to approve Tirzepatide for weight loss sometime this year and we think it could become the best selling drug of ALL TIME. Today on Dumb Money, we'll weigh the data, size-up the opportunity, and give you the skinny on our diet drug investment thesis.
Here are the GLP-1 RA drug makers and their drugs:
Eli Lilly (ticker LLY)
Tirzepatide sold as Mounjaro for diabetes. Weight loss version expected in 2023.
Dulaglutide sold as Trulicity.
Novo Nordisk (ticker NVO)
Semaglutide sold as Ozempic and Rybelsus for diabetes and Wegovy for weight loss.
Liraglutide sold as Victoza for diabetes and Saxenda for weight loss.

3,362 Listeners

1,987 Listeners

398 Listeners

1,842 Listeners

2,159 Listeners

359 Listeners

10,236 Listeners

786 Listeners

446 Listeners

128 Listeners

276 Listeners

600 Listeners

473 Listeners

31 Listeners

82 Listeners